Camp4 Therapeutics (CAMP) sees $4.5 million investment from 5AM Ventures VII, L.P.

On September 11, 2025, 5AM Ventures VII, L.P. purchased 2,941,176 shares of Camp4 Therapeutics Corp (NASDAQ:CAMP) common stock at a price of $1.53, for a total transaction value of $4,499,999. The purchase price represents a significant discount to the current trading price of $2.65, with the stock showing strong momentum, gaining over 33% in the past week. According to InvestingPro data, analysts maintain a bullish stance with price targets ranging from $7 to $21.65.

Following the transaction, 5AM Ventures VII, L.P. directly holds 2,941,176 shares. 5AM Ventures VI, L.P. holds 2,625,145 shares, and 5AM Opportunities II, L.P. holds 302,770 shares. The company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 5.6x. Discover more key financial metrics and 14 additional investment insights with InvestingPro.

In other recent news, CAMP4 Therapeutics Corporation made headlines with a $100 million private placement aimed at advancing its treatment for SYNGAP1-related disorders. The company secured $50 million upfront through the sale of common stock and pre-funded warrants, with the potential to receive an additional $50 million upon reaching specific milestones. This financial boost comes shortly after Piper Sandler adjusted its price target for CAMP4 Therapeutics, lowering it from $18 to $12, while maintaining an Overweight rating on the stock. The research firm highlighted CAMP4’s recent fundraising efforts, which have brought its pro forma cash to approximately $86.1 million, expected to fund operations into 2027.

Meanwhile, Sequans Communications S.A. announced the appointment of Jason W. Cohenour to its Board of Directors. Cohenour, with over 30 years of executive leadership experience, previously served as President, CEO, and Director of Sierra Wireless, Inc. His tenure at Sierra Wireless was marked by a strategic transformation that significantly increased the company’s revenue. These developments reflect ongoing strategic moves within both CAMP4 Therapeutics and Sequans Communications as they navigate their respective industries.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.